ArticleScientific reports2020
The effect of gadolinium-based contrast agent administration on magnetic resonance fingerprinting-based T
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Article
- Review
- Technical note: hydrogel-based mimics of prostate cancer with matched relaxation, diffusion and kurtosis for validating multi-parametric MRI.Medical physics · 2024Article
- Quantitative Analysis of Prostate MRI: Correlation between Contrast-Enhanced Magnetic Resonance Fingerprinting and Dynamic Contrast-Enhanced MRI Parameters.Current oncology (Toronto, Ont.) · 2023Article
- Synthetic MRI in breast cancer: differentiating benign from malignant lesions and predicting immunohistochemical expression status.Scientific reports · 2023Article
- Quantitative longitudinal mapping of radiation-treated prostate cancer using MR fingerprinting with radial acquisition and subspace reconstruction.Magnetic resonance imaging · 2023Article
- Multicenter Repeatability and Reproducibility of MR Fingerprinting in Phantoms and in Prostatic Tissue.Magnetic resonance in medicine · 2022Article
- MR fingerprinting of the prostate.Magma (New York, N.Y.) · 2022Review
- Magnetic resonance fingerprinting in prostate cancer before and after contrast enhancement.The British journal of radiology · 2022Article
- Accelerated 3D whole-brain T1, T2, and proton density mapping: feasibility for clinical glioma MR imaging.Neuroradiology · 2021Article
- MRI-derived radiomics model for baseline prediction of prostate cancer progression on active surveillance.Scientific reports · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
Abstract
Magnetic resonance fingerprinting (MRF) is a rapidly developing fast quantitative mapping technique able to produce multiple property maps with reduced sensitivity to motion. MRF has shown promise in improving the diagnosis of clinically significant prostate cancer but requires further validation as part of a prostate multiparametric (mp) MRI protocol. mpMRI protocol mandates the inclusion of dynamic contrast enhanced (DCE) imaging, known for its significant T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.